SVG-A Cell Line
Invented at Brown University
Msh3-/- SVG-A Cell Line
Invented by Prof Robert Lahue from National University of Ireland, Galway
Invented at National University of Ireland, Galway , Brown University
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 153562 |
| Antigen/Gene or Protein Targets | Msh3 |
| Parental Line | SVG-A immortalized human astrocytes |
| Synonyms | DNA mismatch repair protein Msh3, hMSH3, Divergent upstream protein, DUP, Mismatch repair protein 1, MRP1 |
| Host | Human |
| Tissue | Brain |
| Disease Keywords | Neurodegenerative disease such as Huntington’s |
| Model | Knock-Out |
| Relevance |
The MSH3 gene encodes a DNA mismatch repair protein important in certain cancer types and in certain neurodegenerative diseases. Exon 2 of the MSH3 gene was targeted by CRISPR/Cas9. The resulting Msh3-/- cell line encodes a 3 amino acid deletion in Msh3 that results in 98% loss of Msh3 protein, as judged by western blots with two different antibodies. While ~98% of Msh3 protein is lost in these cells, the abundance of the related proteins Msh2 and Msh6 appear unaffected. This is relevant to DNA mismatch repair. |
| Production Details | Exon 2 of the MSH3 gene was targeted by CRISPR/Cas9. The resulting Msh3-/- cell line encodes a 3 amino acid deletion in Msh3 that results in 98% loss of Msh3 protein, as judged by western blots with two different antibodies. |
| Conditional | No |
| Research Area | Cancer, Cell Cycle, DNA Damage and Repair |
| Growth/Phenotype Keywords | Adherent cell line |
| Recommended Growing Conditions | DMEM supplemented with 10% FBS |
| Positive Control | SVG-A Cell Line, SVG-A Msh3 1.7X Cell Line (derived from Msh3-/- SVG-A Cell Line) |
| Notes |
Applications tested: DNA repair assays Microsatellite instability Trinucleotide expansion assay Cell background for rescue with wild type or variant Msh3 clones Immunoprecipitation control for Msh2-Msh3 protein complex Functional analysis of Msh3 variants CRISPR edited cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license. |
References: 2 entries
Keogh et al. 2017. Nucleic Acids Res. 45(17):10068-10078. PMID: 28973443.
MutSβ abundance and Msh3 ATP hydrolysis activity are important drivers of CTG•CAG repeat expansions.
Europe PMC ID: 28973443
Add a reference
References: 2 entries
Keogh et al. 2017. Nucleic Acids Res. 45(17):10068-10078. PMID: 28973443.
MutSβ abundance and Msh3 ATP hydrolysis activity are important drivers of CTG•CAG repeat expansions.
Add a reference
